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development of post-operative hypotension and hypertension were calcu-
lated using a random-effects model.
Results: Outcomes of 432 patients were studied. Local anaesthetic
blockade of the carotid sinus was associated with a pooled odds ratio of 1.25
(95 per cent c.i. 0.496 to 3.15); p0.216) and 1.28 (95 per cent c.i. 0.699
to 2.33; p0.428) for the development of post-operative hypotension and
hypertension respectively. Although none reach significance there was a
trend towards increased risk of developing a complication in those patients
who received local anaesthetic.
Conclusions: There are insufficient data to determine the role of
intra-operative local anaesthetic administration in reducing post-operative
blood pressure lability following CEA. Conversely, the possibility of harm
cannot be excluded on the basis of the currently available data.
Medical Therapy for Intermittent Claudication
Rowlands T.E., Donnelly R. Eur J Vasc Endovasc Surg 2007;34:314-21.
Medical therapy to improve symptoms, stabilise the underlying vascular
disease and improve lower limb outcomes is an important and effective
adjunct to lifestyle modification and surgical or endovascular interventions
in patients with IC. Randomised placebo controlled trials have shown that
the phosphodiesterase III inhibitor cilostazol 100 mg bid improves pain-
free and maximum walking distance, as well as quality of life, in a range of
patients with intermittent claudication in whom there is no evidence of tissue
necrosis or rest pain. This review summarises the evidence from 8 pivotal
trials of cilostazol involving over 2000 patients with intermittent claudica-
tion treated for up to 6 months. There is comparatively less evidence to
support the use of other treatment modalities for relief of symptoms in
intermittent claudication, but there is considerable interest in therapeutic
angiogenesis to promote new vessel formation and enhance collateralisation
of the lower limb using recombinant growth factor proteins or gene transfer
strategies. The rationale for therapeutic angiogenesis is discussed, together
with the most recent results from randomised trials in patients with periph-
eral arterial disease.
Supervised Exercise Training for Intermittent Claudication: Lasting
Benefit at Three Years
Ratliff D.A., Puttick M., Libertiny G., Hicks R.C.J., Earby L.E, Richards T.
Eur J Vasc Endovasc Surg 2007;34:322-6.
Objectives: To assess the long-term outcome of supervised exercise
training for intermittent claudication.
Methods:A prospective study was undertaken of all patients referred to
a single centre with intermittent claudication (46 m). Patients underwent
supervised exercise training twice weekly for 10 weeks, with regular
follow-up to 3 years. Actual ClaudicationDistance (ACD),MaximumWalking
Distance (MWD) and ankle-brachial pressure indices (ABPI) were measured.
Results: In 202 patients the initial median ACD and MWD were
112 m and 197 m. Following exercise therapy both the median ACD and
MWD increased to 266 m and 477 m at three months, increases of
237% and 242% respectively (p0.001). At three years the median ACD
and MWD were 250 m and 372 m, increases of 223% and 188% respec-
tively (p0.001). There was no significant change in ACD or MWD at
3 months compared to 1, 2 or 3 years. ABPI remained unchanged
throughout.
Conclusions: Supervised exercise training has long term benefit in
patients with intermittent claudication. Results seen at 12 weeks are sus-
tained at three years.
Randomised Trial of Polytetrafluoroethylene Patch Insertion for Re-
current Great Saphenous Varicose Veins
Winterborn R.J., Earnshaw J.J. Eur J Vasc Endovasc Surg 2007;34:367-73.
Objectives: The aim of this study was to assess the possible value of a
polytetrafluoroethylene (PTFE) patch in the treatment of recurrent varicose
veins.
Methods:Thirty-one patients (40 legs) with recurrent saphenofemoral
junction incompetence were randomised to redo saphenofemoral ligation
and great saphenous vein stripping with, or without the insertion of a PTFE
patch over the ligated junction. Patients underwent assessment preopera-
tively, and at 6 weeks, 1 year and 2 years postoperatively with clinical
examination, duplex imaging and completion of the Aberdeen Varicose Vein
Symptom Severity Score (AVVSSS).
Results: A total of 27 patients (32 legs) attended for assessment at 6
weeks, 25 patients (30 legs) at 1 year and 27 patients (32 legs) at 2 years.
At 6 weeks, seven legs (22%) had an area of cutaneous numbness; all but
one had resolved by 1 year. Four legs (13%) developed a groin infection,
which required antibiotics, 2 had a groin haematoma and four had a
seroma, all of which resolved spontaneously. The overall complication
rate was 35% (11 legs), with no statistically significant difference between
the groups. Four of 16 legs without a patch and five of 16 legs with a
patch developed neovascularisation at the saphenofemoral junction on
duplex imaging by two years postoperatively. Two cases of neovasculari-
sation in the patch group and one in the no patch group directly resulted
in clinical recurrence (p1.0). There was an improvement in patients’
AVVSSS two years postoperatively (p0.03), that was similar in both
groups.
Conclusions: In this study, insertion of a PTFE patch did not affect the
rate of perioperative complications and it did not appear to contain neovas-
cularisation.
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